Cargando…

GBP5 Repression Suppresses the Metastatic Potential and PD-L1 Expression in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype because of its high metastatic potential. Immune evasion due to aberrant expression of programmed cell death ligand 1 (PD-L1) has also been reported recently in metastatic TNBC. However, the mechanism underlying metast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Shun-Wen, Chen, Po-Chih, Lin, Min-Hsuan, Ger, Tzong-Rong, Chiu, Hui-Wen, Lin, Yuan-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066311/ https://www.ncbi.nlm.nih.gov/pubmed/33916322 http://dx.doi.org/10.3390/biomedicines9040371

Ejemplares similares

GBP5 Serves as a Potential Marker to Predict a Favorable Response in Triple-Negative Breast Cancer Patients Receiving a Taxane-Based Chemotherapy
por: Cheng, Shun-Wen, et al.
Publicado: (2021)

RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer
por: Yang, Huijie, et al.
Publicado: (2022)

Murine Gbp1 and Gbp2 are ubiquitinated independent of Toxoplasma gondii infection
por: Encheva, Vesela, et al.
Publicado: (2018)

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
por: Khan, Muhammad, et al.
Publicado: (2023)

Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer
por: Ren, Yifan, et al.
Publicado: (2022)

Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer
por: Li, Yijin, et al.
Publicado: (2021)

Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
por: Tang, Yuxia, et al.
Publicado: (2022)

AIM2 upregulation promotes metastatic progression and PD‐L1 expression in lung adenocarcinoma
por: Zheng, Jing‐Quan, et al.
Publicado: (2022)

PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis
por: Yu, Yinan, et al.
Publicado: (2023)

The Gαh/phospholipase C-δ1 interaction promotes autophagosome degradation by activating the Akt/mTORC1 pathway in metastatic triple-negative breast cancer
por: Lin, Hui-Yu, et al.
Publicado: (2020)

NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer
por: Qin, Ge, et al.
Publicado: (2020)

IFN-γ-response mediator GBP-1 represses human cell proliferation by inhibiting the Hippo signaling transcription factor TEAD
por: Unterer, Bea, et al.
Publicado: (2018)

LPS-aggregating proteins GBP1 and GBP2 are each sufficient to enhance caspase-4 activation both in cellulo and in vitro
por: Dickinson, Mary S., et al.
Publicado: (2023)

Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
por: Rozenblit, Mariya, et al.
Publicado: (2020)

Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer
por: Luo, Xiao, et al.
Publicado: (2021)

Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression
por: Xu, Pengfei, et al.
Publicado: (2021)

Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer
por: Tashireva, Liubov A., et al.
Publicado: (2023)

Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1(+) triple negative breast cancer cells
por: Mohan, Nishant, et al.
Publicado: (2019)

PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression
por: Alkaabi, Duaa, et al.
Publicado: (2023)

Observatory wins GBP 10.6m contract
por: Dalton, A W
Publicado: (2003)

Space explorers get GBP35m boost
Publicado: (2002)

Whole exome capture in solution with 3 Gbp of data
por: Bainbridge, Matthew N, et al.
Publicado: (2010)

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
por: Yang, Tinglin, et al.
Publicado: (2023)

The risk of PD-L1 expression misclassification in triple-negative breast cancer
por: Ben Dori, Shani, et al.
Publicado: (2022)

C57BL/6 and 129 inbred mouse strains differ in Gbp2 and Gbp2b expression in response to inflammatory stimuli in vivo
por: Clough, Barbara, et al.
Publicado: (2019)

Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer Cells
por: Chang, Chia-Che, et al.
Publicado: (2021)

GBP2 as a potential prognostic predictor with immune-related characteristics in glioma
por: Li, Ren, et al.
Publicado: (2022)

High‐level expression of ARID1A predicts a favourable outcome in triple‐negative breast cancer patients receiving paclitaxel‐based chemotherapy
por: Lin, Yuan‐Feng, et al.
Publicado: (2018)

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers
por: Barrett, Michael T., et al.
Publicado: (2018)

Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
por: Chen, Xingyu, et al.
Publicado: (2022)

Leaf going nuclear in GBP 2.5m contract
Publicado: (2001)

GBP2 as a potential prognostic biomarker in pancreatic adenocarcinoma
por: Liu, Bo, et al.
Publicado: (2021)

Human GBP1 Is Involved in the Repair of Damaged Phagosomes/Endolysosomes
por: Buijze, Hellen, et al.
Publicado: (2023)

Detection of Cytosolic Shigella flexneri via a C-Terminal Triple-Arginine Motif of GBP1 Inhibits Actin-Based Motility
por: Piro, Anthony S., et al.
Publicado: (2017)

Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer
por: Qi, Yihang, et al.
Publicado: (2022)

Immunotherapy using PD-1/PDL-1 inhibitors in metastatic triple-negative breast cancer: A systematic review
por: Tavares, Dione Fernandes, et al.
Publicado: (2021)

Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer
por: Reguera-Nuñez, Elaine, et al.
Publicado: (2019)

Carboxyl-terminal modulator protein facilitates tumor metastasis in triple-negative breast cancer
por: Lin, Cheng-Han, et al.
Publicado: (2022)

Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer
por: Liu, Hsuan‐Chen, et al.
Publicado: (2023)

Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer
por: Zheng, Xin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_km678jvvq8nk8riampkooaqrfb